Related by context. All words. (Click for frequent words.) 69 colorectal lung 69 pancreatic lung 68 ovarian breast 68 prostate colorectal 67 lung colorectal 66 nonsmall cell lung cancer 66 metastatic colorectal 65 breast colorectal 65 bladder cancers 65 ovarian lung 64 colon pancreas 64 lung pancreatic 64 breast colon 64 lung cancer NSCLC 63 colon prostate 63 prostate pancreatic 63 pancreatic prostate 63 skeletal metastases 63 lung prostate 63 ovarian pancreatic 62 colorectal cancer CRC 62 prostate ovarian 62 prostate colon 62 prostate breast 62 Colon polyps 62 CYT# potent vascular disrupting 62 Basal cell 62 nonmelanoma skin cancers 62 cervical breast 62 colorectal prostate 62 breast pancreatic 61 gastrointestinal cancers 61 metastatic HER2 positive 61 anal cancers 61 colorectal bladder 61 colon breast 61 precursor lesions 61 squamous non 60 Squamous cell 60 neuroendocrine cancers 60 chemotherapy cisplatin 60 invasive lobular 60 gastric pancreatic 60 prostate lung 60 pancreatic bladder 60 metastatic bladder 60 bladder ovarian 60 cancers 60 breast cervical 60 radiation chemoradiation 60 rectal cancers 60 endometrial ovarian 59 recurrent NSCLC 59 metastatic kidney 59 ovarian cervical 59 hormone refractory prostate 59 deCODE ProstateCancer TM 59 lung colon 59 colon esophageal 59 Radical prostatectomy 59 detect precancerous lesions 59 melanoma basal cell 59 breast uterine 59 recurrent metastatic 59 histologies 59 kidney urologic 59 gastrointestinal stromal 59 breast ovarian 59 Menopausal hormone therapy 59 pancreatic colorectal 59 relapsed MM 59 metastatic breast 59 Evoltra ® 59 non squamous 59 HPV vaccine protects 59 ovarian colon 59 colon pancreatic 59 dysplastic lesions caused 59 renal cell carcinomas 59 testicular cancers 58 cervical ovarian 58 neoplasias 58 Squamous 58 HER2 overexpression 58 endometrial kidney 58 Adjuvant chemotherapy 58 ductal breast cancer 58 colon lung 58 colorectal pancreatic 58 endometrial cancers 58 metastatic gastric 58 differentiated thyroid 58 peritoneal cancer 58 unresectable tumors 58 Li Fraumeni 58 metachronous 58 pediatric acute lymphoblastic 58 colorectal cancers 58 squamous cell cancers 58 ovarian endometrial 58 malignant neoplasm 58 recurrent colorectal cancer 58 basal cell carcinoma BCC 58 prostate cancers 58 Colorectal cancer CRC 58 pancreatic cancers 58 pancreatic colon 58 nonmetastatic 58 Folfox 58 nonmelanoma 58 chronic HBV 58 sorafenib tablets 58 cisplatin resistant 58 MAGE A3 ASCI 57 cutaneous melanoma 57 uterine ovarian 57 colorectal cancer 57 Tarceva erlotinib 57 colorectal ovarian 57 heavily pretreated 57 leukemia myeloma 57 advanced adenomas 57 squamous cell skin 57 evaluating tivozanib 57 HRPC ovarian cancer 57 breast ovary 57 Nexavar sorafenib 57 metastatic androgen independent 57 Digital Mammographic Imaging 57 atypical ductal hyperplasia 57 colorectal bowel 57 Screening Trial DMIST 57 metastatic castration resistant 57 leukaemias 57 metastatic castrate resistant 57 lymphoid tumors 57 gemcitabine chemotherapy 57 nonmelanoma skin cancer 57 squamous cell carcinoma SCC 57 chronically immunosuppressed solid 57 lung ovarian 57 postoperative chemotherapy 57 breast endometrial 57 metastatic pancreatic 57 gastric cancers 57 pancreatic NET 57 Epithelial ovarian cancer 57 sunitinib malate 57 esophagus colon 57 AML MDS 57 uterine cancers 57 castrate resistant 57 standard chemotherapy regimen 57 endometrial hyperplasia 57 nonalcoholic steatohepatitis 57 medullary thyroid cancer 57 stage IIIb IV 57 ovarian colorectal 57 colorectal gastric 57 squamous cell 57 Velcade bortezomib 57 malignant brain 57 grade cervical intraepithelial 57 resistant hormone refractory 57 stage IIIB IV 56 erlotinib Tarceva ® 56 unresectable liver cancer 56 vinca alkaloids 56 Basal Cell 56 bladder prostate 56 invasive ductal 56 hormone receptor negative 56 MabThera Rituxan 56 Xelox 56 Herceptin trastuzumab 56 tanned indoors 56 cisplatin chemotherapy 56 squamous 56 myelofibrosis polycythemia vera 56 hepatocellular cancer 56 dasatinib Sprycel 56 HER2 positive cancers 56 neuroendocrine tumors 56 follicular lymphoma FL 56 lung cancers 56 precancerous cervical lesions 56 Uterine cancer 56 cutaneous malignancies 56 bowel cancers 56 leukemia lymphoma multiple myeloma 56 deCODE BreastCancer 56 malignant neoplasms 56 gastroesophageal junction 56 prostate cancer CaP 56 oesophageal adenocarcinoma 56 Bayer Nexavar 56 penile cancers 56 breast prostate 56 Medullary thyroid cancer 56 trastuzumab Herceptin ® 56 endometriosis ovarian cysts 56 hematological disorders 56 squamous cell lung cancer 56 esophageal cancers 56 vaginal lesions 56 advanced metastatic prostate 56 commonest cancers 56 relapsed ovarian cancer 56 Acute lymphoblastic leukemia 56 colorectal 56 colorectal adenoma 56 malignancies 56 Alessandro Riva 56 malignant pleural mesothelioma 56 bone metastasis 56 lobular carcinoma 56 European Randomized Study 56 Hepatocellular Carcinoma HCC 56 cancer mCRC 56 Taxotere docetaxel 56 cirrhosis liver failure 56 adrenocortical cancer 56 atypical hyperplasia 56 intestinal metaplasia 56 anthracycline taxane 56 adenomatous polyps 56 relapsing remitting MS RRMS 56 acute leukemias 56 undergone radical prostatectomy 56 pancreatic carcinoma 56 metastatic GIST 56 lymphoma Hodgkin lymphoma 56 medically inoperable 55 malignant polyps 55 precancers 55 pancreatic islet cell 55 paclitaxel Taxol ® 55 prostate TURP 55 distant metastasis 55 gynecological cancers 55 hematologic disorders 55 Ixempra 55 Acute myeloid leukemia 55 vulvar vaginal 55 seminoma 55 ixabepilone 55 metastatic lung cancer 55 ZACTIMA 55 papillary renal cell carcinoma 55 superficial basal cell carcinoma 55 grade gliomas 55 systemic ALCL 55 gynecologic cancers 55 osteosarcomas 55 gastrointestinal stromal tumors GISTs 55 serous ovarian cancer 55 abnormal Pap smears 55 Pap smear screening 55 abnormal Pap tests 55 advanced metastatic renal 55 anal lesions 55 docetaxel Taxotere 55 squamous cell carcinomas 55 hormonal therapies 55 H. pylori eradication 55 pediatric malignancies 55 GnRH agonists 55 lymphomas leukemias 55 cetuximab Erbitux 55 premalignant 55 metastatic renal cell 55 recurrent glioblastoma multiforme 55 CIN2 + 55 HBeAg negative 55 bladder cervix 55 colorectum 55 Recombinant interferon alpha 55 human papillomaviruses HPV 55 Fludara ® 55 Gardasil protects 55 Papillary 55 pulmonary metastases 55 hormone refractory metastatic prostate 55 hormonally sensitive 55 Chronic Myelogenous Leukemia CML 55 colon rectal cancer 55 BR.# 55 colorectal adenomas 55 pancreatic ovarian 55 prostate specific 55 opioid induced constipation OIC 55 cranial radiation 55 BCIRG 55 Pancreatic neuroendocrine tumors 55 dacarbazine chemotherapy 55 cervical uterine 55 esophagus pancreas 55 peritoneal carcinomatosis 55 Peginterferon alfa 2b 55 gastrointestinal GI cancers 55 acute promyelocytic leukemia APL 55 colorectal neoplasms 55 cause mesothelioma asbestosis 55 Zolinza 55 Glioblastoma multiforme GBM 55 gene BRCA2 55 doxorubicin Adriamycin 55 adjuvant therapies 55 Malignant Melanoma 55 tumor xenograft models 55 iniparib 55 K ras mutations 55 cancerdefine 55 Renal Cell Carcinoma RCC 55 basal cell nevus syndrome 55 docetaxel Taxotere ® 55 solar keratosis 55 mesotheliomas 55 oropharyngeal cancer 55 grade serous ovarian 55 diffuse gastric 55 abiraterone acetate 55 nasopharyngeal carcinoma 55 ano genital warts 55 capecitabine Xeloda 55 leukemia ALL 55 prostate carcinomas 54 Adenomas 54 nasopharyngeal cancer 54 preoperative chemotherapy 54 advanced adenoma 54 benign neoplasms 54 Chlamydia infections 54 cabazitaxel 54 cervical vulvar 54 PSMA ADC 54 eribulin mesylate 54 Human papillomavirus HPV 54 Vandetanib 54 metastatic colon cancer 54 HNSCC 54 benign prostatic hyperplasia enlarged 54 Tavocept 54 metastatic malignant melanoma 54 hematological diseases 54 external genital lesions 54 nodal metastasis 54 carcinoid tumors 54 leukemia AML 54 leukemias lymphomas 54 antigen PSA 54 BRCA deficient 54 FOLFOX6 54 LHRH receptor positive 54 hematologic cancers 54 oral leukoplakia 54 Candida infection 54 Acute myeloid leukemia AML 54 unresectable stage 54 ToGA 54 faulty BRCA genes 54 deCODE BreastCancer TM 54 contralateral breast 54 trastuzumab DM1 54 Kit CD# positive 54 brivanib 54 Oesophageal cancer 54 standard chemotherapy regimens 54 allogeneic HSCT 54 Acute myelogenous leukemia 54 Salvatore Glorioso mayor 54 therapeutic regimens 54 curable cancers 54 CIN3 + 54 Rectal cancer 54 recurrent malignant glioma 54 hepatorenal syndrome 54 colon cancers 54 erlotinib Tarceva 54 Idiopathic pulmonary fibrosis 54 oral clodronate 54 cervical carcinoma 54 chronic periodontitis 54 indolent follicular non 54 immunological diseases 54 TTR amyloidosis 54 hepatocellular carcinomas 54 cytoreduction 54 pelvic malignancies 54 subependymal giant cell 54 HER2 positive metastatic breast 54 macrovascular events 54 advanced HER2 positive 54 epithelial tumors 54 Avastin bevacizumab 54 lymphoma subtypes 54 lenalidomide Revlimid R 54 androgen independent 54 Erbitux cetuximab 54 Surgical resection 54 vaginal cancers 54 axitinib 54 indolent NHL 54 receptor tyrosine kinase inhibitor 54 Chronic lymphocytic leukemia 54 sickle cell cystic fibrosis 54 colorectal cancer incidence 54 gemcitabine carboplatin 54 CHD CVD 54 metastatic neuroendocrine tumors 54 biliary tract cancer 54 ovarian cancers 54 HIV HCV coinfected 54 carcinoma HCC 54 tumors GIST 54 completely resected 54 malignant lymphoma 54 refractory chronic lymphocytic 54 NovoTTF 54 mycophenolate mofetil 54 recurrent glioblastoma multiforme GBM 54 thalidomide Thalomid 54 pharyngeal cancer 54 diseases fat malabsorption 54 Leukemias 54 pancreas colon 54 basal cell carcinomas 54 Renal cell carcinoma 54 basal cell cancers 54 castrate resistant prostate cancer 54 lung malignant melanoma 54 refractory metastatic 54 decompensated liver disease 54 metastatic renal 54 prostate adenocarcinoma 54 pain palliation 54 Jevtana 54 endometrial carcinoma 54 Thyroid nodules 54 Gleevec imatinib mesylate 54 CLL SLL 54 often detect precancerous 54 Androgen deprivation therapy 54 HPV-#/# 54 smoldering myeloma 54 cediranib 54 gemcitabine Gemzar 53 histologic subtype 53 GARDASIL ® 53 clinically localized prostate 53 Hodgkin lymphoma HL 53 adjuvant radiotherapy 53 AVASTIN 53 anti angiogenic agents 53 Alimta pemetrexed 53 LHRH analogues 53 Waldenstrom macroglobulinemia 53 soft tissue sarcomas 53 recurrent myocardial infarction 53 precancerous cervical 53 investigational monoclonal antibody 53 ocular disorders 53 non squamous NSCLC 53 intestinal polyps 53 testicular germ cell 53 Relapsing remitting MS 53 genital herpes infections 53 adenoma recurrence 53 myeloproliferative neoplasms 53 doublet chemotherapy 53 vinca alkaloid 53 gastrointestinal stromal tumors 53 antibody MAb 53 regorafenib 53 Paraplatin ® carboplatin 53 gastrointestinal stromal tumors GIST 53 MGd 53 Vicinium TM 53 cervical dysplasia 53 pleural mesothelioma 53 gynecologic malignancy 53 gastric adenocarcinoma 53 liposomal doxorubicin 53 stage IIIB 53 recurrent ovarian cancer 53 BRAF mutations 53 pre cancerous growths 53 afatinib 53 BRCA2 mutations 53 androgen suppression therapy 53 Gastric cancer 53 H. pylori infection 53 Fludarabine 53 Routine screening 53 GISTs 53 liver metastasis 53 methylation markers 53 lymphocytic leukemia 53 Nexavar tablets 53 cutaneous T cell 53 Chronic myeloid leukemia CML 53 penile anal 53 containing granisetron 53 colorectal polyp 53 fallopian tube cancers 53 docetaxel Taxotere R 53 herpes zoster shingles 53 CMV disease 53 Taxotere ® 53 bevacizumab Avastin 53 mapatumumab 53 adenocarcinomas 53 lung carcinomas 53 Afatinib 53 carcinoid 53 cervical lesions 53 Troxatyl 53 PCA3 scores 53 KRAS mutations occur 53 SCCHN 53 pancreatic adenocarcinoma 53 palliative radiotherapy 53 lymphomas 53 gastrointestinal stromal tumor GIST 53 LungAlert TM 53 premalignant lesions 53 pancreatic gastric 53 familial pancreatic cancer 53 Tarceva TM 53 PCNSL 53 Colorectal cancer screening 53 T#I mutant 53 node metastases 53 Virulizin ® 53 metastatic hormone refractory 53 EGFR mutation positive 53 Squamous cell carcinomas 53 Endometrial cancer 53 rectal cancer 53 abnormal pap smears 53 darapladib 53 Lung transplantation 53 basal cell skin 53 pancreatic neuroendocrine tumors 53 aflibercept VEGF Trap 53 Chronic lymphocytic leukemia CLL 53 Pemetrexed 53 gynecologic malignancies 53 pre cancerous polyps 53 temsirolimus 53 Merck KGaA Erbitux 53 imatinib Gleevec 53 advanced neoplasia 53 IgG1 monoclonal antibody 53 Basal cell carcinoma 53 keloid scarring 53 colon tumors 53 tumor subtypes 53 squamous histology 53 gastrointestinal mucositis 53 simplex virus 53 Tay Sachs thalassemia 53 biliary cancer 53 Cholangiocarcinoma 53 Amrubicin 53 nonvaccine 53 HGPIN 53 alpha interferons 53 cutaneous squamous cell carcinoma 53 Human papillomavirus 53 malignant melanomas 53 colorectal liver 53 acyclovir Lauriad R 53 Novartis Gleevec 53 lung cancer asbestosis 53 ELOXATIN 53 recurrent bladder 53 androgen ablation 53 Carcinoid tumors 53 hormonally responsive 53 ASCUS 53 EGFR expressing 53 figitumumab 53 Chronic myeloid leukemia 53 Aplidin 53 HCV infections 53 IV malignant melanoma 53 commercialize deforolimus 53 EGFR tyrosine kinase inhibitors 52 temozolomide Temodar 52 ductal carcinomas 52 grade cervical dysplasia 52 gefitinib Iressa 52 Stomach cancer 52 trastuzumab Herceptin R 52 chlamydial infection 52 non alcoholic steatohepatitis 52 neuroendocrine carcinoma 52 protease inhibitors PIs 52 Torisel 52 adenomatous polyp 52 gastroenteritis conjunctivitis 52 colorectal carcinoma 52 prostate cancer mCRPC 52 specific antigen PSA 52 androgen deprivation 52 Sezary syndrome 52 carboplatin paclitaxel 52 ovarian uterine 52 Shark cartilage 52 respiratory viral infections 52 CERVARIX ® 52 chemopreventive agents 52 polyp recurrence 52 malignant lymphomas 52 Epratuzumab 52 nonproliferative 52 HER2 positive breast cancer 52 colonoscopy sigmoidoscopy 52 sunitinib Sutent 52 small lymphocytic lymphoma 52 gastric cardia 52 invasive candidiasis 52 recurrent glioblastoma 52 precancer 52 TNF blocker therapy 52 Glioblastoma Multiforme 52 EGFR mutation 52 metastatic prostate 52 gastric carcinoma 52 5 FU leucovorin 52 aromatase inhibitors AIs 52 advanced hepatocellular carcinoma 52 dysplastic nevi 52 esthesioneuroblastoma rare form 52 cervical precancers 52 esophageal tumors 52 invasive carcinomas 52 ZACTIMA TM ZD# 52 prostate carcinoma 52 basiliximab 52 mutated KRAS gene 52 ACTEMRA TM 52 urothelial bladder cancer 52 nonsquamous 52 anal penile 52 oncogenic HPV 52 operable breast cancer 52 progesterone receptor negative 52 non hodgkin lymphoma 52 commonly mutated genes 52 pneumococcal strains 52 commercializes oncology 52 Brain metastases 52 neoplastic lesions 52 Quinamed 52 lung cancer 52 myelofibrosis MF 52 lymph node enlargement 52 Stage IIIb 52 hormone deprivation 52 refractory multiple myeloma 52 stage IIIA 52 surgical debulking 52 alvespimycin 52 Theratope 52 thymoma 52 hypereosinophilic syndrome 52 oncological indications 52 cilengitide 52 chemo resistant 52 Benign breast 52 allogeneic bone marrow 52 inconclusive Pap 52 pemphigus vulgaris 52 thyroid cancers 52 follicular thyroid cancer 52 imatinib Gleevec ® 52 Benign prostatic hyperplasia BPH 52 ovarian carcinoma 52 hepatocellular carcinoma 52 hematologic abnormalities 52 Noxafil 52 promoter hypermethylation 52 overt hepatic encephalopathy HE 52 microtubule inhibitor 52 cervical intraepithelial neoplasia 52 TTF Therapy 52 histologic subtypes 52 breast carcinomas 52 colorectal tumors 52 untreated metastatic pancreatic 52 bacteremic pneumonia 52 lobular cancer 52 mRCC 52 olaparib 52 pertuzumab 52 colorectal polyps 52 myelodysplastic syndrome MDS 52 lung adenocarcinoma 52 chemotherapeutic regimen 52 HER2 positive 52 Malignant gliomas 52 Gliomas 52 PROLARIS 52 CIN3 52 myelomas 52 monoclonal antibody therapies 52 Sentinel node biopsy 52 acute lymphoid leukemia 52 Peritoneal mesothelioma 52 gastrointestinal malignancies 52 lymphatic cancers 52 advanced epithelial ovarian 52 precancerous growths 52 synovial cell 52 curative resection 52 non polyposis colorectal 52 hepatocellular carcinoma liver 52 haematological malignancies 52 Vaccine Recombinant 52 postoperative pathology 52 KRAS mutant 52 recurrent squamous cell carcinoma 52 Chlamydia trachomatis infection 52 muscular dystrophy cystic fibrosis 52 postmenopausal hormone 52 AA Amyloidosis 52 castration resistant 52 OvaRex ® MAb 52 ER CHOP 52 melanoma 52 systemic fungal infections 52 investigational therapies 52 pan HDAC inhibitor 52 ErbB2 positive 52 bile duct cancers 52 symptomatic BPH 52 Hurthle cell 52 Allovectin 7 52 Acute leukemia 52 colorectal carcinomas 52 recurrent ovarian 52 TEMODAL 52 asthma emphysema bronchitis 52 neoadjuvant therapy 52 refractory indolent non 52 mesothelioma asbestosis 52 systemic scleroderma 52 advanced medullary thyroid 52 cholangiocarcinoma 52 leukemia APL 52 unresectable metastatic 52 hematopoietic cancers 52 Malignant melanoma 52 dysplastic lesions 52 LRP5 52 pre cancerous lesions 52 severe oral mucositis 52 Zyclara Cream 52 pegylated interferon alpha 52 sorafenib Nexavar ® 52 Axitinib 52 circulating rotavirus 52 oropharyngeal candidiasis OPC 52 gastrointestinal stromal tumor 52 chemoradiotherapy 52 EGFRIs 52 hepatocellular carcinoma HCC 52 Crohns disease 51 oral pharyngeal 51 ductal cancer 51 BRAF inhibitor 51 anaplastic thyroid carcinoma 51 carcinoid cancer 51 Sutent sunitinib 51 cervix uteri 51 cervical cancer precursors 51 breast cancer recurrences 51 eosinophilic pneumonia 51 bilateral oophorectomy 51 mycobacterial infections 51 invasive lobular carcinoma 51 premalignant lesion 51 paclitaxel carboplatin 51 bevacizumab Avastin ® 51 chronic eosinophilic leukemia 51 basal cell cancer 51 Glioblastoma Multiforme GBM 51 axillary dissection 51 Cancer Incidence Mortality 51 hyperplasia BPH 51 IMC #B 51 GlaxoSmithKline Cervarix 51 Colorectal cancers 51 vismodegib 51 hereditary predisposition 51 Xanafide 51 Ceflatonin 51 taxane therapy 51 Prostate Cancer ERSPC 51 cervical cancer genital warts 51 gynecological malignancies 51 oncogenic HPV types 51 Human papilloma virus 51 dysglycemia 51 Phase #b/#a clinical 51 thromboembolic disease 51 familial amyloidotic polyneuropathy FAP 51 benign proliferative breast 51 neratinib 51 glioma rarer 51 lymphocytosis 51 Folate deficiency 51 papillary carcinoma 51 pCR 51 recurrent genital herpes 51 hematopoietic malignancies 51 mucinous 51 HPVs 51 epithelial cancers 51 serotype #A 51 atypical Hemolytic Uremic Syndrome 51 haematologic malignancies 51 intravenous bisphosphonates 51 Cloretazine 51 Stomach stapling 51 prostate bladder 51 CP CPPS 51 abnormal mammograms 51 pituitary adenomas 51 prophylactic vaccines 51 noncancer 51 secondary hyperparathyroidism 51 beta carotene supplementation 51 sarcomas 51 HGS# 51 actinic keratosis AK 51 adjuvant radiation 51 metastatic brain tumor 51 pertussis vaccines 51 parathyroid carcinoma 51 epithelial ovarian cancer 51 prostate cancer CRPC 51 assessing T DM1 51 Brentuximab Vedotin SGN 51 fallopian tube carcinoma 51 Hycamtin 51 anticancer therapy 51 chlamydial infections 51 Gleevec imatinib 51 carcinoma HNSCC 51 docetaxel chemotherapy 51 metastatic lesions 51 metastatic CRC 51 precancerous tumors 51 refractory colorectal cancer 51 colon cancer 51 CHOP chemotherapy 51 b Hib 51 NSABP 51 HRPC 51 sorafenib Nexavar 51 phase IIb study 51 platinum refractory 51 myeloproliferative disorders 51 childhood sunburns 51 hematologic malignancies 51 radiofrequency ablation RFA 51 delayed onset CINV 51 Infusion reactions 51 relapsed acute lymphoblastic 51 signal transduction inhibitors 51 ADVEXIN therapy 51 Celiac disease affects 51 cervical cancers 51 TGFBR1 * 6A 51 forodesine 51 chronic myeloid 51 estrogen receptor negative 51 minimally symptomatic metastatic castrate 51 Inhaling asbestos fibers 51 metastatic carcinoid 51 Irinotecan 51 Human Papilloma Virus HPV 51 bacterium Neisseria meningitidis 51 preventing genital warts 51 malignant pancreatic 51 locoregional recurrence 51 leukemias 51 oesophageal cancers 51 oligodendrogliomas 51 Globocan 51 pneumococcal illnesses 51 follicular non 51 Follicular Lymphoma 51 ovary uterus 51 Helicobacter pylori H. pylori 51 nonalcoholic steatohepatitis NASH 51 neoplasia PIN 51 patients undergoing chemotherapy 51 Synovial sarcoma 51 refractory chronic myeloid 51 BRCA2 gene mutation 51 superficial bladder cancer 51 nutlin 3a 51 B Cell Lymphoma 51 alkylating agent 51 dasatinib Sprycel ® 51 candidemia 51 cutaneous T 51 KRAS status 51 papillary 51 VaD 51 BCG refractory 51 colon rectal 51 ZADAXIN ® 51 samalizumab 51 transplantation HCT 51 venous blood clots 51 Folic acid supplements 51 carcinoids 51 5-FU/LV 51 oral ridaforolimus 51 Bronchiectasis 51 hepatic metastases 51 metastatic renal cell carcinoma 51 homozygous familial hypercholesterolemia 51 proliferative disorders 51 acute myeloid 51 lung metastases 51 metastatic RCC 51 neoadjuvant treatment 51 HGS ETR1 mapatumumab 51 benign breast 51 pheochromocytoma 51 undergoing radical prostatectomy 51 venous thromboembolic events 51 lobular breast cancer 51 bronchogenic carcinoma 51 Ectopic pregnancy 51 urothelial carcinoma 51 malignant growths 51 Human Papilloma Virus 51 Phase Ib II 51 Cell Non Hodgkin 51 acute onset CINV 51 Esophageal cancer 51 vulvar cancers 51 Cloretazine ® 51 acute coronary syndromes ACS 51 TREANDA 51 Non Hodgkin lymphoma 51 genital sores 51 YONDELIS 51 HER2 positive breast 51 adenomatous 51 non metastatic osteosarcoma 51 LUX Lung 51 carcinomas 51 Nimotuzumab 51 herpes chlamydia 51 aerodigestive tract 51 MAGE A3 51 Canvaxin 51 cervical neoplasia 51 KRAS mutant tumors 51 malignant lesions 51 histological subtypes 51 histological subtype 51 Insegia 51 pneumococcal pneumonia 51 metastatic basal cell 50 situ LCIS 50 intra abdominal abscess 50 mTOR inhibitors 50 refractory AML 50 hepatitis C HCV 50 lung adenocarcinomas 50 proteasome inhibitor 50 benign prostatic hypertrophy 50 relapsed leukemia 50 chronic viral infections 50 neoplastic diseases 50 NSCLC 50 Gorlin syndrome 50 repigmentation 50 epithelial ovarian 50 TEAEs 50 pT2 50 cyclophosphamide doxorubicin vincristine 50 imatinib resistance 50 invasive cervical cancers 50 PANVAC VF 50 Aflibercept 50 BRCA2 mutation carriers 50 huC# DM4 50 Teverelix 50 Acute Myeloid Leukaemia AML